Kolneb

Colistimethate Sodium, the active ingredient in Kolneb, is a Polymyxin antibiotic presented as an inhalation for inhalation use. It treats chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients.

GNH USA supplies Kolneb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies, clinics and research institutions worldwide.

Kolneb is a polymyxin antibiotic used to manage chronic bacterial airway infections in cystic fibrosis. - Chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: reduces bacterial burden and helps preserve lung function. - Persistent airway colonisation by Pseudomonas aeruginosa in cystic fibrosis: aids in long‑term suppression of the pathogen. - Multidrug‑resistant Gram‑negative respiratory infections in cystic fibrosis: provides an alternative option when other agents fail.

Kolneb may cause a range of adverse reactions, most of which are related to its local pulmonary administration and systemic absorption.

Common Side Effects: - Cough: irritation of the airways may provoke a persistent cough. - Bronchospasm: transient narrowing of the bronchial tubes can occur during inhalation. - Throat irritation: patients often report soreness or a burning sensation in the throat. - Taste disturbance: a metallic or salty taste is frequently noted.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Respiratory failure: marked decline in breathing function, especially in vulnerable patients. - Nephrotoxicity: systemic absorption can impair kidney function. - Ototoxicity: potential hearing loss or balance disturbances, particularly with high cumulative exposure.

Before prescribing Kolneb, clinicians should evaluate patient‑specific risk factors and monitor for potential complications. - Renal function monitoring: assess serum creatinine and eGFR regularly due to possible nephrotoxicity. - Auditory assessment: perform baseline and periodic hearing tests to detect ototoxic effects. - Bronchospasm risk: pre‑treat with bronchodilators in patients with reactive airway disease. - Hepatic impairment: use caution in patients with cystic fibrosis‑related liver disease. - Store at room temperature: keep in the original container, protect from moisture and light.

Colistimethate Sodium can interact with several drug classes, influencing safety and efficacy.

Major Interactions (Avoid): - Neuromuscular blocking agents (e.g., vecuronium): increased risk of muscle weakness and respiratory compromise. - Aminoglycosides (e.g., gentamicin): additive nephrotoxicity and ototoxicity.

Moderate Interactions (Monitor Closely): - Loop diuretics (e.g., furosemide): may enhance renal toxicity; monitor renal parameters. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): potential for increased kidney injury; assess renal function. - Rifampin: may reduce colistin plasma levels, diminishing efficacy; consider therapeutic drug monitoring.